Interleukin‐6 receptor antagonist therapy to treat SARS‐CoV‐2 driven inflammatory syndrome in a kidney transplant recipient
| Autor: | Ranjit Nair, Ashraf I Reyad, Ann Dao, Jacfranz J. Guiteau, Machaiah Madhrira, Sridhar R. Allam, Philip B. Antiporta |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
2019-20 coronavirus outbreak
Transplantation biology business.industry Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viruses Interleukin-6 Receptor Antagonist virus diseases medicine.disease biology.organism_classification Kidney transplant recipient chemistry.chemical_compound Tocilizumab Infectious Diseases chemistry Pandemic Immunology Medicine business skin and connective tissue diseases Letters to the Editor Letter to the Editor Kidney transplantation Betacoronavirus |
| Zdroj: | Transplant Infectious Disease |
| ISSN: | 1399-3062 1398-2273 |
| DOI: | 10.1111/tid.13326 |
| Popis: | Coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is a pandemic that is evolving rapidly at present with unprecedented global health and societal implications. Herein, we report a case of successful treatment of SARS‐CoV‐2 induced inflammatory syndrome by utilization of the interleukin‐6 receptor antagonist (IL‐6Ra) tocilizumab. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|